Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective

Area of Science:

• Hepatology
• Oncology
• Interventional Radiology

Background:

• Hepatocellular carcinoma (HCC) disproportionately affects Asia, with high incidence and mortality rates.
• Many HCC patients in Asia are diagnosed with unresectable disease, limiting treatment options.
• Existing staging systems like the Barcelona Clinic Liver Cancer (BCLC) algorithm show regional variations in application, particularly in Asia.

Purpose of the Study:

• To review the indications, contraindications, and technical variations of embolotherapy for unresectable HCC in Asia.
• To explore combination regimens and optimal timing for initiating, repeating, or discontinuing embolotherapy.
• To provide insights into the application of transarterial chemoembolization (TACE) for HCC patients at various stages.

Main Methods:

• Literature review focusing on studies and guidelines related to HCC staging and treatment in Asian regions.
• Analysis of data on the prevalence, diagnosis, and treatment of HCC, with a specific emphasis on embolotherapy.
• Synthesis of information regarding the efficacy and safety of different embolotherapy approaches.

Main Results:

• Embolotherapy is a widely adopted treatment for HCC across all stages in many Asian guidelines, despite discrepancies in its application for unresectable HCC.
• Significant variations exist in the allocation and protocols for embolotherapy among different Asian regions.
• The review highlights the need for standardized guidelines on the use of embolotherapy for unresectable HCC.

Conclusions:

• Embolotherapy plays a crucial role in managing unresectable HCC in Asia, but its application requires careful consideration of indications, techniques, and timing.
• Further research and consensus are needed to optimize embolotherapy protocols and improve patient outcomes for HCC in Asia.
• Standardizing TACE application can enhance its effectiveness for a broader range of HCC patients.